B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Cp (NQ: TECH )

72.45 -1.40 (-1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Techne Cp

< Previous 1 2 3 Next >
Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout
 
Via Benzinga
Analyst Expectations for Bio-Techne's Future
 
Via Benzinga
Earnings Outlook For Bio-Techne
 
Via Benzinga
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Bio-Techne: Q1 Earnings Insights
Bio-Techne (NASDAQ:TECH) reported its Q1 earnings results on Tuesday, November 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Bio-Techne Q4 Earnings
  Bio-Techne (NASDAQ:TECH) reported its Q4 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Bio-Techne Q3 Earnings
Bio-Techne (NASDAQ:TECH) reported its Q3 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
 
Via Benzinga
Bio-Techne Clocks 17% Organic Revenue Growth In Q2, Announces $400M Share Buyback
Bio-Techne Corporation (NASDAQ: TECH) has posted Q2 FY22 s 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
 
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 429 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 574 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 265 companies made new 52-week lows. 
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Tackling Recurring Health Conditions Offers Hope to Patients
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly... 
Via FinancialNewsMedia
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
7 Defensive Growth Stocks to Buy for a Shaky Market
These are the best defensive growth stocks to invest in now. Each of these can make great investments if/when the market sours. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
 
Via Benzinga
7 Superior Stocks That Smart Investors Will Buy on the Dip
The recent sell-off presents long-term investors with many robust stocks to buy on the dip. These seven provide a start. 
Via InvestorPlace
10 Biggest Price Target Changes For Wednesday
Keybanc lifted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Here's How Much You Would Have Made Owning Bio-Techne Stock In The Last 5 Years
Bio-Techne (NASDAQ:TECH) has outperformed the market over the past 5 years by 17.84% on an annualized basis. Buying $1,000.00 In TECH: 5 years ago, an investor could have... 
Via Benzinga
Bio-Techne Corporation (TECH) Q1 2022 Earnings Call Transcript
TECH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.